RCKT vs. TGTX, DYN, ARVN, KROS, RYTM, VERA, MRVI, MRUS, CORT, and AMPH
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include TG Therapeutics (TGTX), Dyne Therapeutics (DYN), Arvinas (ARVN), Keros Therapeutics (KROS), Rhythm Pharmaceuticals (RYTM), Vera Therapeutics (VERA), Maravai LifeSciences (MRVI), Merus (MRUS), Corcept Therapeutics (CORT), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical preparations" industry.
Rocket Pharmaceuticals (NASDAQ:RCKT) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings.
98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 31.1% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 9.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Rocket Pharmaceuticals presently has a consensus price target of $52.13, suggesting a potential upside of 120.59%. TG Therapeutics has a consensus price target of $29.00, suggesting a potential upside of 107.44%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than TG Therapeutics.
In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 13 mentions for Rocket Pharmaceuticals and 11 mentions for TG Therapeutics. Rocket Pharmaceuticals' average media sentiment score of 0.13 beat TG Therapeutics' score of 0.10 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.
TG Therapeutics has a net margin of 5.42% compared to Rocket Pharmaceuticals' net margin of 0.00%. TG Therapeutics' return on equity of 12.89% beat Rocket Pharmaceuticals' return on equity.
TG Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Rocket Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500.
TG Therapeutics received 279 more outperform votes than Rocket Pharmaceuticals when rated by MarketBeat users. Likewise, 76.71% of users gave TG Therapeutics an outperform vote while only 72.12% of users gave Rocket Pharmaceuticals an outperform vote.
Summary
TG Therapeutics beats Rocket Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
